Ellex Medical Lasers (ASX:ELX) has announced additional scientific research validating the method of action of the company’s proprietary Retinal Rejuvenation Therapy (2RT) for the treatment of early age-related macular degeneration.
Research found that directly following treatment by 2RT of the targeted retinal pigment epithelium (RPE) cells, the surrounding, surviving cells grew into the vacated spaces and stimulated expression of a range of protein factors, triggering a regenerative effect on nearby RPE cells.
This confirmed the positive cellular response induced by 2RT, validating its previously postulated method of action.
It offers the potential for 2RT to emerge as a platform technology that could provide additional, alternative therapeutic applications.
The research is expected to be published in a peer-review publication during the 2016 financial year.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.